#FabricheAperte”: the AssoGenerici initiative kicks off from ZETA Farmaceutici in Vicenza

Fedaisf editorial staff

September 12, 2015

Not just savings: AssoGenerici member companies open their doors to show politicians, journalists and local administrators the quality of their production and the socio-economic impact of a sector that employs 10,000 people in 60 companies in Italy

(VI), 11 September 2015 – The main Italian production centers of equivalent drugs open their doors to the press, politicians and local administrators. The initiative started today from ZETA Farmaceutici in Sandrigo (VI). # Open Factories, launched by AssoGenerici to make the general public and decision-makers aware of the productive, employment and economic value of Italian companies active in the generic drug segment, already highlighted by the study on the sector prepared by Nomisma and presented on 5 May.

# Open Factories it is also an opportunity to promote correct information on the quality standards of equivalent medicines, many of which are produced in Italy by the same companies that also synthesize them on behalf of large "branded" drug companies, following the most stringent requirements of the "Good Manufacturing Practices" (GMP).

At today's appointment in ZETA Pharmaceuticals Also present were Senator Enrico Cappelletti, the honorable Federico Ginato, deputy, and the honorable Flavio Zanonato, MEP.

Zeta Farmaceutici employs a total of 244 people and in 2014 recorded a turnover of 84 million Euros, with production almost equally divided between manufacturing for third parties and the synthesis of its own products.

Founded as a pharmaceutical workshop after World War II, the company is one of the founding members of Assogenerici and boasts recognized specific expertise in the field of pharmacopoeia, which still makes it a partner of various Italian and international groups for Research & Development activities.

“‘Fabbriche aperte’ è innanzitutto un’operazione di trasparenza, che va di pari passo con la progressiva affermazione del farmaco equivalente in Italia – ha detto Enrique Häusermann, Presidente di AssoGenerici. “Bisogna ricordare – ha proseguito Häusermann – che i farmaci generici rappresentano oggi il 19,5% di tutte le confezioni di medicinali dispensate in Italia, pari al 10,7% della spesa farmaceutica. É importante, quindi, che citizens and decision-makers can ascertain that this considerable share of medicines used every day in Italy are often also produced in our country, according to the highest quality standards, employing personnel almost always residing in the areas where the production centers are located".

“Non ci sono solo i 230 milioni l’anno di risparmio per il SSN tra gli effetti positivi della diffusione dei farmaci equivalenti – ha continuato Häusermann -, ma anche 10mila posti di lavoro garantiti agli addetti del settore presso ben 60 aziende operanti sul territorio nazionale. Un vero e proprio sprint imprenditoriale, produttivo e occupazionale, che si aggiunge all’ampliamento del numero di cittadini i cui bisogni di salute vengono soddisfatti, grazie al generico”. “Gli equivalenti infatti – ha concluso Häusermann – per la loro efficacia, sicurezza e qualità garantita da una produzione di eccellenza, come è il caso di Zeta Farmaceutici sono i principali alleati dell’aderenza terapeutica e dell’accesso alle cure, soprattutto a quelle primarie”.

ASSOGENERICI – Comunicato stampa – 09/09/2015

The EU bans 700 generic medicines produced in India

USA. Voluntary recall of generic Indian hypertension drugs from the market

Suspension of generic drugs. Mylan: "We are collaborating with national and international authorities"

Certain drugs a little too generic

Equivalent generic or brand name? The opinion of the (real) experts